Literature DB >> 20682752

Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention.

Balpreet Bhogal1, Thomas A Jongens.   

Abstract

Fragile X syndrome (FXS) is a cognitive disorder caused by silencing of the fragile X mental retardation 1 gene (FMR1). Since the discovery of the gene almost two decades ago, most scientific contributions have focused on identifying the molecular function of the fragile X mental retardation protein (FMRP) and understanding how absence of FMR1 gene expression gives rise to the disease phenotypes. The use of model organisms has allowed rapid progression in the FXS field and has given insight into the molecular basis of the disease. The mouse and fly FXS models have enabled studies to identify potential targets and pathways for pharmacological treatment. Here, we briefly review the two primary FXS model systems and describe how studies in these organisms have led us closer to therapeutic treatments for patients afflicted with FXS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682752      PMCID: PMC2965397          DOI: 10.1242/dmm.002006

Source DB:  PubMed          Journal:  Dis Model Mech        ISSN: 1754-8403            Impact factor:   5.758


  98 in total

1.  Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression.

Authors:  K M Huber; M S Kayser; M F Bear
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

2.  Localization of a short-term memory in Drosophila.

Authors:  T Zars; M Fischer; R Schulz; M Heisenberg
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

3.  Mushroom body ablation impairs short-term memory and long-term memory of courtship conditioning in Drosophila melanogaster.

Authors:  S M McBride; G Giuliani; C Choi; P Krause; D Correale; K Watson; G Baker; K K Siwicki
Journal:  Neuron       Date:  1999-12       Impact factor: 17.173

4.  Evidence that fragile X mental retardation protein is a negative regulator of translation.

Authors:  B Laggerbauer; D Ostareck; E M Keidel; A Ostareck-Lederer; U Fischer
Journal:  Hum Mol Genet       Date:  2001-02-15       Impact factor: 6.150

5.  Fragile X mice develop sensory hyperreactivity to auditory stimuli.

Authors:  L Chen; M Toth
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

6.  Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein.

Authors:  L Wan; T C Dockendorff; T A Jongens; G Dreyfuss
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study.

Authors:  Shelli R Kesler; Amy A Lightbody; Allan L Reiss
Journal:  Am J Med Genet A       Date:  2009-03       Impact factor: 2.802

8.  Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome.

Authors:  Giulia Curia; Thomas Papouin; Philippe Séguéla; Massimo Avoli
Journal:  Cereb Cortex       Date:  2008-09-11       Impact factor: 5.357

9.  Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures.

Authors:  Laura K K Pacey; Scott P Heximer; David R Hampson
Journal:  Mol Pharmacol       Date:  2009-04-07       Impact factor: 4.436

10.  A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

Authors:  E Berry-Kravis; D Hessl; S Coffey; C Hervey; A Schneider; J Yuhas; J Hutchison; M Snape; M Tranfaglia; D V Nguyen; R Hagerman
Journal:  J Med Genet       Date:  2009-01-06       Impact factor: 6.318

View more
  17 in total

Review 1.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.

Authors:  Catherine H Choi; Brian P Schoenfeld; Eliana D Weisz; Aaron J Bell; Daniel B Chambers; Joseph Hinchey; Richard J Choi; Paul Hinchey; Maria Kollaros; Michael J Gertner; Neal J Ferrick; Allison M Terlizzi; Nicole Yohn; Eric Koenigsberg; David A Liebelt; R Suzanne Zukin; Newton H Woo; Michael R Tranfaglia; Natalia Louneva; Steven E Arnold; Steven J Siegel; Francois V Bolduc; Thomas V McDonald; Thomas A Jongens; Sean M J McBride
Journal:  J Neurosci       Date:  2015-01-07       Impact factor: 6.167

Review 3.  Involvement of Rho-family GTPases in axon branching.

Authors:  Mirela Spillane; Gianluca Gallo
Journal:  Small GTPases       Date:  2014-03-11

4.  In vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylation.

Authors:  R Lane Coffee; Ashley J Williamson; Christopher M Adkins; Marisa C Gray; Terry L Page; Kendal Broadie
Journal:  Hum Mol Genet       Date:  2011-11-11       Impact factor: 6.150

Review 5.  Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond.

Authors:  Christina Gross; Elizabeth M Berry-Kravis; Gary J Bassell
Journal:  Neuropsychopharmacology       Date:  2011-07-27       Impact factor: 7.853

Review 6.  Drosophila modeling of heritable neurodevelopmental disorders.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Curr Opin Neurobiol       Date:  2011-05-17       Impact factor: 6.627

7.  Fragile X mental retardation protein is required for programmed cell death and clearance of developmentally-transient peptidergic neurons.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Dev Biol       Date:  2011-05-10       Impact factor: 3.582

8.  Using Drosophila as a tool to identify Pharmacological Therapies for Fragile X Syndrome.

Authors:  Sean M McBride; Sandra L Holloway; Thomas A Jongens
Journal:  Drug Discov Today Technol       Date:  2012-09-24

Review 9.  RNA-binding protein misregulation in microsatellite expansion disorders.

Authors:  Marianne Goodwin; Maurice S Swanson
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

10.  Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome.

Authors:  M K King; R S Jope
Journal:  Genes Brain Behav       Date:  2013-08-29       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.